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Nitric oxide synthasePreeclampsia (PE) is characterized by hypertension and proteinuria. It has been classiﬁed in early or late
according to gestational age at the onset of disease. Endothelial dysfunction plays a crucial part in its
pathogenesis. NO is a potent vasodilator and ADMA is its endogenous inhibitor. We have assessed mater-
nal ADMA levels. ADMA were increased in early [0.66 lmol/L] versus late sPE [0.47 lmol/L] (P = 0.001)
and versus normotensive pregnant [0.48 lmol/L] (P = 0.001). Our ﬁndings suggest that high ADMA levels
in early sPE could compromise NO synthesis contributing to endothelial dysfunction, leading to impaired
placentation and the onset of this disease.
 2013 Elsevier Inc. All rights reserved.Introduction
Preeclampsia (PE) is characterized by hypertension and protein-
uria occurring after the 20th week of pregnancy in women who
have had no previous symptoms. Clinically, it is important to diag-
nose the severe form of the disease, in which blood pressure and
proteinuria are much higher [1]. According to gestational age
(GA) at the onset of disease, PE has been classiﬁed as early
(GA<34 weeks) and late (GAP34 weeks) [2]. Although the etiology
of PE is unclear, the predisposition to endothelial dysfunction [3],
which may trigger abnormal placentation and haemostatic and
inﬂammatory systems is thought to play a crucial part in its path-
ogenesis [4,5].
Nitric oxide (NO) is a free radical, produced by several cell
types, from L-arginine, in a reaction catalyzed by the NO-synthase
(NOS). NO produced by endothelial cells has emerged as a versatile
mediator involved in many endothelium functions including ﬂow-
mediated vasodilatation and platelet activation inhibition [6].
Asymmetric dimethylarginine (ADMA) is synthesized by post-
translational modiﬁcation, involving the addition of two methyl
groups from the donor methionine to arginine residues in proteins.
This reaction is catalyzed by an enzyme called protein arginine
methyltransferase (PRMT) type 1. These methylated proteins are
predominantly found in the nucleus and play a role in RNAprocessing and transcriptional control [7]. ADMA is released into
the cytosol when these proteins are hydrolyzed, thereby being an
obligatory product of protein turnover. Thus, the amount of ADMA
generated depends on the extent of arginine methylation in pro-
teins and on the rate of protein turnover. Although the kidney
plays an important role in the elimination of ADMA from the body,
by excreting it into the urine [8], the conversion of ADMA by
dimethylarginine dimethylaminohydrolase (DDAH Iand II) into cit-
rulline and dimethylamine is the most important metabolic path-
way [9]. In 1992, Vallance and Leone ﬁrstly described that ADMA
is an endogenous inhibitor of the arginine-NO pathway [10]. From
then, its role in regulating NO production has attracted increasing
attention.
Since a role of NO in pathogenesis of PE has been admitted
[11,12], we hypothesized that high ADMA levels that compromise
the NO synthesis resulting in local endothelial dysfunction might
be one important event in PE.Methods
We have assessed maternal ADMA plasma levels by ELISA
(Diagnostika GMBH) in 29 women with early severe PE (sPE), 24
women with late sPE and 50 normotensive pregnant. The inclusion
criteria for severe PE were blood pressure P160  110 mmHg, ta-
ken in two different measurements with a minimum interval of 2 h
between them and after rest, and proteinuriaP2 g in 24 h urine or
higher than (++) by the qualitative strip method in random urine
sample [1]. Early and late sPE were classiﬁed according the GA at
the onset of disease (< or P34 weeks, respectively) [2]. For the
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diastolic blood pressure 6120  80 mmHg, with noformer record
of hypertension and PE, as well as absence of proteinuria. Exclusion
criteria common for the three groups were chronic hypertension,
twin pregnancy, haemostatic abnormalities, cancer, diabetes, and
cardiovascular, autoimmune, renal and hepatic diseases and anti-
coagulant or corticosteroids therapy. Data statistical analysis was
performed using SPSS 13.0 software, by Mann–Whitney test.Results
ADMA levels were increased in the early sPE [0.66 lmol/L
(0.52–0.78)] comparing to late sPE [0.47 lmol/L (0.42–0.60)]
(P = 0.001) and to normotensive pregnant [0.48 lmol/L (0.42–
0.58)] (P = 0.001). No difference was observed comparing late sPE
and normotensive pregnant.Discussion
Previous studies reported elevated maternal ADMA levels in
preeclamptic women [13–17]. Speer et al. 2008 [17] related that
pregnant who develop PE had higher ADMA levels in the ﬁrst half
of pregnancy comparing to those that keep normotensives. Savvi-
dou et al., 2003 [14] showed that increased ADMA levels preceded
the clinical onset of the disease and these molecule were higher at
the 23–25ª weeks of gestation which develops PE. Sandrim et al.,
2010 [15] found a negative association between ADMA and nitrite
(a marker of NO production) levels in preeclamptic Brazilian wo-
men, comparing to normotensive pregnant.
It is known that in healthy pregnancy, maternal ADMA levels
falls until up to 24 weeks of gestation before rising to pre-preg-
nancy levels towards term [17]. This change mirrors the initial fall
and subsequent rise in maternal vascular tone and blood pressure
during normal gestation. As the median of GA of women with early
sPE enrolled in our study was 31 weeks, while in normotensive
group was 32, the difference in ADMA levels cannot be explained
by physiological variations of ADMA throughout pregnancy.
It has been admitted that early sPE is associated with ischemic
placental lesions, while in late sPE an adequate or slightly impaired
placentation occurs [18].
DDAH II is highly expressed in placenta [19] and protein turn-
over in developing fetoplacental unit is high [20], which suggest
a large local production of ADMA.
Besides, since an oxidative stress occurs in PE during early pla-
cental development [21] and there is evidence that DDAH is sensi-
tive to oxidative inactivation [22], it could be admitted a decrease
in DDAH leading to systemic endothelial dysfunction.
Additionally, it has been proposed that high ADMA levels could
affect angiogenesis, since the growth factors activity such as vascu-
lar endothelial growth factor (VEGF), placental growth factor and
basic ﬁbroblast growth factor are mediated by NO-dependent
mechanisms [23,24]. A decrease in VEGF expression in culture of
endothelial cells by ADMA was demonstrated, suggesting that this
protein may affect not only growth factors activity but also their
production [25].
To the best of our knowledge, it is the ﬁrst study assessing
ADMA levels in early and late sPE. Our ﬁndings suggest that high
ADMA levels in early sPE could compromise NO synthesis contrib-
uting to endothelial dysfunction, leading to impaired placentation
and the onset of this disease. Besides, our results also corroborate
to admit that physiopathology of early and late PE is distinct, as
suggested by reports on the literature.Acknowledgments
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